Dried-blood spot screening for cystic fibrosis in the newborn

PubMed

Insights

Serum-immunoreactive-trypsin (IRT) is elevated in infants with cystic fibrosis (CF). A new dried blood-spot assay for IRT shows promise as a newborn screening test for CF.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Early diagnosis of CF is crucial for timely intervention and improved outcomes.
  • Serum-immunoreactive-trypsin (IRT) is a biomarker associated with pancreatic dysfunction in CF.

Purpose of the Study:

  • To measure serum-immunoreactive-trypsin (IRT) levels in children diagnosed with cystic fibrosis (CF).
  • To evaluate the potential of a dried blood-spot assay for IRT as a newborn screening tool for CF.

Main Methods:

  • Serum samples were collected from children with CF and control groups.
  • Immunoreactive-trypsin (IRT) levels were quantified in serum.
  • A novel assay using dried blood spots for IRT measurement was developed and validated.

Main Results:

  • All infants diagnosed with CF exhibited elevated serum-IRT levels within the first few months of life.
  • The established dried blood-spot assay demonstrated feasibility for IRT measurement.
  • The assay showed potential for widespread application in newborn screening programs.

Conclusions:

  • Elevated serum-IRT is a consistent finding in early infancy for children with CF.
  • A dried blood-spot IRT assay is a viable method for newborn screening.
  • This assay could facilitate early detection and management of cystic fibrosis.